We hypothesize that the newly emerged ROS1 rearrangement occurs because the cell subset carrying ROS1 gradually becomes the predominant pathological type of adenocarcinoma following pembrolizumab treatment. This evidence concerns the gene ROS1 and adenocarcinoma.